Yan SX, et al. - Using the National Cancer Database (NCDB), researchers assessed stereotactic body radiation therapy (SBRT) dose prescription patterns and survival outcomes in Stage II NSCLC. Between 2004–2013, patients diagnosed with Stage II NSCLC and treated with SBRT were identified in NCDB. They calculated the biologically effective dose with α/β = 10 Gy (BED₁₀). According to results, 10 Gy x 5 (35.9%) and 12 Gy x 4 (19.3%) were the most common prescriptions. In patients treated with SBRT, median overall survival was 23.7 months. In the United States, SBRT is rarely used to treat Stage II NSCLC. Higher BED₁₀ treatment was associated with enhanced survival, and the benefit was limited to node-negative disease patients.